Two forces are pulling the tape in opposite directions and, for once, the calendar gives everyone a breather: US stock and bond markets are closed today for Juneteenth (they reopen Monday). The relief story keeps building — the US–Iran deal is now in force, Iranian cargo ships are sailing home for “business as usual,” Trump is set to release ~$6bn of frozen funds in phases, and the Strait of Hormuz is reopening fast enough that crude is heading for a weekly loss (Brent back near $78, ~38% off its spring war peak). Against that sits Kevin Warsh’s hawkish Fed: with the easing bias gone and the dot-plot tilted to a possible hike, the dollar is firmer, gold slid (Goldman lopped $500 off its target) and the 10-year sits ~4.45%. Wall Street still managed a chip-led bounce into the holiday — the live Bloomberg ticker shows the S&P +1.08% and Nasdaq +1.91% at Thursday’s close — while Europe slipped as oil majors weighed.
Europe/Rome 06:00 · US markets closed · Juneteenth · US–Iran deal in force · Hormuz reopening · Warsh hawkish · gold & oil lower
▶ Listen · audio briefing (~5 min)
Equity levels are Thursday 18 June’s closes from the live Bloomberg “Top Securities” ticker read this morning; the 10-year, FX, crude and gold reflect the live overnight read. US stock and bond markets are closed today (Fri 19) for Juneteenth and reopen Monday 22 — expect thin global liquidity. The swing factors from here: the pace of Hormuz normalisation and whether the “glut” call holds, the durability of the post-Warsh rate-hike pricing, and the US–Iran 60-day clock now that JD Vance and Israel are publicly at odds over the terms.
Top of the morning
US–Iran deal takes hold — ships sail home, but Vance and Israel clash over the terms
With the interim accord signed, tracking data shows Iranian cargo vessels leaving Malaysian waters and heading back to the Gulf, and Abu Dhabi is already telling buyers to load shipments from inside Hormuz. Washington will release roughly $6bn of frozen Iranian money — held in Qatar — in phases as Tehran “behaves,” while Iran keeps its ballistic missiles. The friction has shifted to allies: JD Vance lashed out at the Israeli government over its criticism of the deal and has put a planned trip to Switzerland for further talks on hold, with a 60-day countdown now running.
Wall Street bounces into a long weekend — but the US is shut today
Chips led a rebound from Wednesday’s hawkish-Fed sell-off: the live Bloomberg ticker has the S&P 500 at 7,500.58 (+1.08%) and the Nasdaq at 26,517.93 (+1.91%) at Thursday’s close. Today both the equity and bond markets are closed for Juneteenth, so price discovery passes to Asia and Europe on thin volumes. The undertone is still Warsh’s: the dollar is firmer, gold fell and the 10-year holds ~4.45% as traders keep at least one rate rise on the table.
Oil heads for a weekly loss as the war premium fully unwinds
Crude is set to end the week lower — Brent slipped back toward $78, its weakest since late February, with flows through Hormuz seen at their strongest pace since the conflict began and Saudi, UAE and Iraqi barrels poised to restart. The FT’s framing has flipped from “$200 and shortages” to “looming gluts.” The disinflationary dividend is already showing up: Russia is expected to cut its key rate as the oil-driven inflation jolt eases, even as Western central banks stay cautious.
US tells ASML it’s worried China may already have its most advanced chip tool
In a Bloomberg exclusive, Washington has raised concerns with ASML that China may have obtained its top-end lithography equipment — a fresh twist in the export-control fight that sits right on top of the AI-hardware supply chain. It lands alongside a quieter squeeze: with component makers prioritising data centres, FT reports console makers like Nintendo and Sony are seeing prices rise as supply tightens — the same chip scarcity, viewed from the consumer end.
The AI build-out leans harder on Wall Street — while some customers start rationing
Meta has tapped former Goldman banker Dina Powell McCormick to help mine debt markets for AI financing; SpaceX is plotting a bond deal of at least $20bn after its record IPO; and a German grid-equipment maker, SGB-SMIT, is eyeing a >€4bn float on the data-centre boom. But the cost side is biting: Amazon, Walmart and Uber are among early adopters now capping or discouraging wasteful AI usage (“we created a monster”), and Anthropic is managing a model-rollout fiasco after JPMorgan cut Claude access for Hong Kong staff. Voracious demand, increasingly credit- and policy-entangled.
US opens a tariff probe of Germany over drug pricing
Washington has launched a Section 301 investigation into Germany’s spending on new medicines, alleging “persistent underpayment for innovative pharmaceutical products” — a sharp escalation of the transatlantic drug-pricing fight. For the pharma complex it adds a policy overhang on European price-setting just as the sector navigates US most-favoured-nation pressure; a theme worth watching for any branded-drug holding.
Burnham wins his seat and sets up a challenge to Starmer
Andy Burnham took the Makerfield by-election and will return to Parliament as an MP, telling supporters voters “voted for change” — positioning the Greater Manchester mayor to mount a Labour leadership challenge to Keir Starmer. Bloomberg frames it as reinforcing the argument that Burnham can counter Farage in battleground seats. A slow-burn UK political risk rather than a market mover, but the leadership question is now live.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. The myFT feed still sketches a higher-for-longer regime with a friendlier energy tail. Rates are the dominant signal: FT calls Warsh’s “hawkish shift” one that is upending global currency bets — expectations of a Fed hike have reversed emerging-market and commodity-currency trades, lifted the dollar (EUR/USD ~1.14, cable ~1.32) and argue for continued duration caution. The offset is oil: with Hormuz reopening and barrels set to return, FT now frames crude as a coming glut, Brent under $80 — energy disinflation that drains the stagflation tail but doesn’t soften the Fed. The flag most relevant to your war-chest discipline is credit: FT warns insurers are becoming “dangerously addicted” to private-credit ratings and that regulatory arbitrage is going unchecked, echoing Bloomberg’s read that private-credit turmoil has retail investors eyeing the exits. Froth and rising stress — not yet a severe systemic trigger. Net: stance stays neutral-to-defensive, war-chest rules sheathed.
ASML & semiconductors (held name + your semis shelf). The clearest single-name signal: the US has told ASML it is concerned China may already have its most advanced chip tool — an export-control overhang for the lithography monopoly and, by extension, the whole AI-hardware chain (Broadcom, the foundries). The same chip scarcity is turning consoles into “accidental luxury goods.” Watch for any ASML or Commerce Department follow-through.
AI capex & cloud (Microsoft, Alphabet, Amazon, Broadcom — theme). Demand is intact but the funding mix and cost discipline are the watch-items: Meta is reaching for Wall Street debt, SpaceX is plotting a ≥$20bn bond, and data-centre IPOs are queuing — a capex wave leaning on credit. Counter-signal: Amazon, Walmart and Uber are now capping AI usage as costs strain budgets, an efficiency turn that could pressure consumption-based cloud revenue at the margin.
Healthcare / pharma (Novo Nordisk, Eli Lilly, Vertex, UnitedHealth — theme). No single-name readouts, but a policy flag: the US Section 301 probe into Germany’s drug pricing escalates the transatlantic pricing war and adds an overhang to European branded-drug economics. The clinical action is in the desk below — a cardiology- and trials-heavy NEJM issue, no GLP-1 readout today.
Payments (Visa, Mastercard) · slow-burn risk. Bloomberg’s Markets cover (cross-read) again has Europe fighting to loosen America’s grip on payment systems and hunting alternatives to the US card networks on sovereignty grounds. No near-term catalyst, but a recurring structural watch-item for the duopoly.
Berkshire / industrials (Caterpillar, Deere, Booking) · quiet. No held-name items in today’s feed; the cyclical read is indirect — cheaper energy is a cost tailwind, a firmer dollar a translation headwind.
Shelf single-names live today: ASML (US export-control concern over China access — the day’s clearest catalyst) and Amazon (AI-cost caps). Everything else is theme-level — an AI capex/credit watch, a US–Germany pharma-pricing probe, and a private-credit stress flag set against a hawkish Warsh Fed and an oil slide FT calls a coming glut.
Net: the relief is real — a deal in force and crude near multi-month lows ease the stagflation tail — but a hawkish Fed, a firmer dollar, softer gold, and visible AI-credit and private-credit froth keep the regime neutral-to-defensive. No severe trigger, so war-chest rules stay sheathed. Watch-lines: Hormuz reopening pace and the “glut” call, post-Warsh rate-hike pricing and the 10-year, ASML / export-control headlines, and AI-sector & private-credit funding supply.
Markets snapshot
Read this morning from the live Bloomberg “Top Securities” ticker. Equity indices are Thursday 18 June closes; the 10-year, FX, crude and gold show the live overnight read. US cash equity and bond markets are closed today for Juneteenth.
Instrument
Last
Move / context
S&P 500
7,500.58
+1.08% · Thu close; chip-led rebound
Nasdaq Composite
26,517.93
+1.91% · Thu close; chips lead the bounce
FTSE 100
10,399.70
−1.04% · snapped a 5-day win streak, oil majors weigh
US 10-year Treasury
4.45%
flat on the day, up on the week · Warsh hawkish regime
EUR/USD
1.14
dollar firmer on the hawkish Fed
GBP/USD
1.32
softer · Goldman calls sterling the most overvalued G10
Crude Oil (WTI)
$76.01
heading for a weekly loss · Brent ~$78; Hormuz reopening, glut focus
Gold (spot)
$4,164.10
−1.9% · weekly loss; Goldman cuts target $500 on no Fed cuts
Levels transcribed from the Bloomberg Europe ticker this morning. The week’s signature is the split between a hawkish Fed and a de-escalating Gulf: stocks rebounded and crude eased toward a weekly loss, while gold gave back ground and the dollar firmed as cut bets turned to hike bets. With the US shut for Juneteenth, today’s tape is an Asia/Europe affair on light volume; next live US session is Monday.
Global markets & macro
The rates regime that Kevin Warsh reset on Wednesday is still doing the heavy lifting. The Fed held but stripped out its easing bias, eliminated explicit forward guidance, and published projections in which at least one further hike is now the central case — a response to inflation pushed toward double the 2% target by the spring energy shock. The bond market has internalised it: the 10-year sits near 4.45%, the dollar is firmer (EUR/USD ~1.14, sterling ~1.32), and FT reports the “hawkish shift” is unwinding crowded emerging-market and commodity-currency carry trades. Gold is the clean casualty — it slid toward $4,164 and is set for a weekly loss as haven demand drains and Goldman cut its target by $500 on the view that there will be no Fed cuts this year. Equities, though, leaned the other way into the holiday: a chip-led rebound carried the S&P up 1.08% and the Nasdaq 1.91% on Thursday, the “resilient US” trade reasserting itself even with the higher-for-longer overlay. Europe was the laggard, snapping a five-day winning streak as oil majors weighed.
The energy side is where the relief concentrates. With the Iran deal in force and Hormuz reopening at the fastest pace since the war began, crude is heading for a weekly decline — Brent near $78, roughly 38% below its spring peak — and the market’s mental model has flipped from shortage to glut as Saudi, UAE and Iraqi barrels prepare to return. That disinflationary dividend is already visible abroad: Russia is expected to cut its key rate as the oil-driven price jolt fades. Underneath the indices, the capital-markets plumbing keeps rewriting itself on credit. Meta is reaching into Wall Street debt markets — via Dina Powell McCormick — to fund its AI build, SpaceX is preparing a bond of at least $20bn after its record IPO, and data-centre-linked IPOs are lining up; against that, FT flags insurers growing “dangerously addicted” to private-credit ratings and Bloomberg notes retail investors eyeing the private-credit exits. The confidence vote on compute is real, but it is concentrating risk in exactly the corner — private and AI-linked credit — that a higher-for-longer Fed makes more fragile.
Geopolitics & world news
The Middle East has moved from war to an uneasy, transactional peace. With the US–Iran accord now in force, Iranian cargo ships are tracking home to the Gulf for “business as usual,” Abu Dhabi is directing buyers to load inside Hormuz, and Washington has agreed to release roughly $6bn of Iranian funds parked in Qatar in phases — with Tehran retaining its ballistic missiles, the concession critics seize on. The fault line has moved inside the Western camp: Vice-President JD Vance publicly rebuked the Israeli government over its criticism of the deal and shelved a planned trip to Switzerland for follow-on talks, just as a 60-day implementation clock begins. Shipping is watching the fine print — industry executives warn the accord’s language could eventually let Tehran levy Hormuz transit fees once the interim period lapses.
Elsewhere the blocs keep re-drawing. EU leaders, meeting in Brussels, opted to delay a trade confrontation with China, choosing dialogue over immediate action for fear of retaliation even as they warned about imbalances; the bloc is also moving to remove barriers to banks’ cross-border capital flows to close the gap with US rivals. Ukraine launched a record drone attack on Moscow, targeting a refinery and disrupting airports, while Austria’s chancellor argued Europe should keep talking to Putin amid “momentum” on peace. And in Britain, Andy Burnham’s Makerfield by-election win returns him to Parliament and opens a path to challenge Keir Starmer. For the markets reader, the throughline is a world simultaneously de-escalating its hot war and hardening its economic borders. The clinical reader’s deep-dive follows below.
Clinical desk · NEJM this week
For the medical reader
Read this morning from the pinned NEJM current-issue eTOC feed (Vol 394, No 23, 18 June 2026) — a trials-heavy issue spanning infectious disease, vascular and structural cardiology, trauma and a first-in-class genetic-epilepsy therapy. The RSS carries only titles, so each result below was looked up against the NEJM abstract and conference/registry coverage; numbers are summarised, not reproduced.
Cefazolin for MSSA bacteraemia — SNAP platform (positive; practice-supporting). Within the international Bayesian platform trial SNAP, adults with penicillin-resistant, methicillin-susceptible S. aureus bacteraemia were randomised open-label to cefazolin versus an antistaphylococcal penicillin (flucloxacillin/cloxacillin). On the primary endpoint of 90-day all-cause mortality, cefazolin was non-inferior — and it caused less acute kidney injury. Takeaway: reassurance for cefazolin as a first-line option in MSSA bacteraemia, with a cleaner renal profile where flucloxacillin nephrotoxicity is a concern.
C-TRACT — iliac-vein stenting for post-thrombotic syndrome (positive). In 225 patients with imaging-confirmed iliac-vein obstruction and moderate-to-severe PTS, endovascular therapy (stenting plus intensified antithrombotics) beat standard care alone: mean Venous Clinical Severity Score at 6 months 8.1 vs 10.0, with better health-related quality of life. The cost is bleeding — overall bleeding rose, though major events stayed uncommon. The accompanying editorial calls it “a step forward”: the first randomised support for stenting in established PTS, to be offered with eyes open on bleeding risk.
ODYSSEY-HCM — mavacamten in nonobstructive HCM (negative). A phase 3, placebo-controlled trial across 201 sites tested the cardiac myosin inhibitor in symptomatic nonobstructive hypertrophic cardiomyopathy. At 48 weeks it missed both co-primary endpoints — no significant improvement in the KCCQ-23 clinical summary score or in peak VO₂ on cardiopulmonary exercise testing versus placebo. Takeaway: despite the mechanistic rationale, mavacamten’s benefit does not extend beyond obstructive disease — it keeps Camzyos confined to the obstructive phenotype and leaves nonobstructive HCM without a disease-modifying drug.
Prehospital whole blood in traumatic haemorrhage — SWiFT and a companion RCT (neutral/negative; landmark pairing). The UK SWiFT trial randomised 616 patients with life-threatening traumatic bleeding to up to two units of prehospital whole blood versus standard components. The composite of death or massive transfusion at 24 hours was essentially identical — 48.7% with whole blood vs 47.7% with components — and 30-day mortality was numerically higher with whole blood (25.9% vs 20.5%). Published alongside a second randomised trial of prehospital type O whole blood, with an editorial noting the two give “consistent” evidence. Takeaway: a cold-water result for prehospital whole-blood momentum — the logistics and cost now have to justify themselves against no demonstrated survival edge.
Zorevunersen in Dravet syndrome (positive; first-in-class). Pooled phase 1–2a open-label data (MONARCH and ADMIRAL) in 81 children and adolescents tested this intrathecal antisense oligonucleotide, which up-regulates functional Na₋1.1 channels to correct the underlying SCN1A defect. At the 70 mg dose, median convulsive-seizure frequency fell roughly 59–91% across monthly intervals over the first 20 months, with durable gains in cognition and behaviour extending through three years of open-label follow-up. The phase 3 EMPEROR trial is enrolling, with a readout targeted for mid-2027. Takeaway: the first credible signal of disease modification — not just seizure suppression — in a devastating genetic epilepsy.
Also in the issue: a clinical review on the management of differentiated thyroid cancer (a practical refresher on risk-stratified surgery, radioiodine and TSH suppression); a sobering global-health correspondence on intravenous artesunate in artemisinin-resistant severe malaria in Uganda, underscoring spreading partial resistance in Africa; perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer; and outbreak reporting on Sudan virus disease in Uganda and an Andes hantavirus update.
Provenance: read this morning from Luca’s pinned NEJM current-issue eTOC feed (Vol 394, No 23, 18 June 2026) via Control Chrome; the second (cardiology/ahead-of-print) NEJM tab was not open at run time, so cardiology and trial results were supplemented and cross-checked via web search against NEJM abstracts and ACC / ESC / Healio / TCTMD coverage. Summarised, not reproduced verbatim; not clinical advice.
Today & week ahead (CET)
Fri 19US stock & bond markets CLOSED — Juneteenth (reopen Mon 22) · Japan CPI (May) came in steady as subsidies restrained energy; BOJ’s Himino flags upside price risk · EU Council summit, Brussels (China imbalances, US–Iran fallout) · thin holiday liquidity — watch oil & tanker logistics as Hormuz reopens
Mon 22US markets reopen · first live read on post-Juneteenth positioning and the post-Warsh rate path
WatchPost-Warsh rate-hike pricing & the 10-year · Hormuz reopening pace & the “glut” call · US–Iran 60-day clock and Vance–Israel friction · ASML / export-control follow-through · AI-sector bond & private-credit supply (Meta financing, SpaceX ≥$20bn) · US Section 301 pharma probe of Germany